FDA Issues Second Warning to Novo Nordisk Over Misleading Ozempic Advertisements and Risk Disclosure Failures

The U.S. Food and Drug Administration (FDA) has issued a second formal warning letter to pharmaceutical giant Novo Nordisk regarding its promotional activities for the GLP-1 drug Ozempic (semaglutide). The regulatory action cites violations related to misleading claims and inadequate risk disclosure in the company's advertising materials. The FDA's Office of Prescription Drug Promotion (OPDP) identified specific promotional communications that allegedly overstate the efficacy of Ozempic or present unsubstantiated claims, while simultaneously failing to communicate the drug's associated risks with the prominence and clarity required by law. This marks the second such enforcement letter from the FDA to Novo Nordisk concerning the promotion of its blockbuster diabetes and weight-loss medication, indicating a pattern of non-compliance with federal advertising regulations. The warning letter demands that Novo Nordisk immediately cease disseminating the violative promotional materials and provide a comprehensive corrective action plan. Failure to adequately address the FDA's concerns can lead to further regulatory action, including monetary penalties or other sanctions. The incident highlights ongoing scrutiny of pharmaceutical marketing practices, particularly for high-profile drugs like Ozempic that have achieved widespread consumer recognition and significant market penetration.